Latest Breaking News On - Guo liang yu - Page 1 : comparemela.com

Apollomics Announces Private Placement Financing and Addition to Board of Directors

Apollomics Announces Private Placement Financing and Addition to Board of Directors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPeter vozzoGuo liang yuCanaccord genuityJonathan wangRobert bob linSean leousMedicine departmentApollomics incSecurities exchangeLawrence berkeley laboratoryExchange commissionAnnounces private placement financingInternal medicine departmentChief executive officerSecurities act

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene

Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongPeter vozzoSean leousGuo liang yuNational medical products administrationNational medical products administration of chinaSecurities exchangeApollomics incAvistone biotechnology coAnnounces approvalFirst in class treatmentAvistone biotechnologyNew drug applicationCentral nervous systemMet exon

Vebreltinib Receives NMPA Approval in China for MET Fusion+ Glioma

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

Chin neurosurgGuo liang yuWorld health organizationApollomics incChina national medical products administrationNational medical products administrationKarnofsky performance statusGlobal oncologyBrain cancer

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR.

San diegoUnited statesSean leousGuo liang yuPeter vozzoSecurities exchangeEuropean society of medical oncology congress onExchange commissionApollomics incAmerican association for cancer researchAvistone biotechnology coNational medical products administrationCancer researchAnnual meetingChief executive officerAvistone biotechnology

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesGuo liang yuPeter vozzoSean leousMatthew plunkettExchange commissionDrug administrationMaxpro capital acquisition corpSecurities exchangeApollomics incHighlights clinical progressReports full yearChief executive officerNew drug applicationMet exonBreakthrough therapy